Results from a Pooled Analysis of Two European, Randomized, Placebo-Controlled, Phase 3 Studies of ATX-101 for the Pharmacologic Reduction of Excess Submental Fat

BACKGROUND: The injectable adipocytolytic drug ATX-101 is the first nonsurgical treatment for the reduction of submental fat (SMF) to undergo comprehensive clinical evaluation. This study aimed to confirm the efficacy and safety of ATX-101 for SMF reduction through a post hoc pooled analysis of two...

Descripción completa

Detalles Bibliográficos
Autores principales: McDiarmid, James, Ruiz, Jesus Benito, Lee, Daniel, Lippert, Susanne, Hartisch, Claudia, Havlickova, Blanka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175004/
https://www.ncbi.nlm.nih.gov/pubmed/24984785
http://dx.doi.org/10.1007/s00266-014-0364-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175004/
https://www.ncbi.nlm.nih.gov/pubmed/24984785
http://dx.doi.org/10.1007/s00266-014-0364-9

Ejemplares similares